
About Balaxi
Balaxi is a publicly listed company based in Hyderabad (India) founded in 1942 by Ashish Maheshwari. Drug distribution and storage services are provided by Balaxi. The company has 197 employees. Its Indian entity Balaxi Pharmaceuticals Limited reported revenue of ₹273 Cr. Balaxi offers products and services including Pharmaceutical Products and Branded Consumer Products. Its focus areas include Traditional Pharmaceuticals, Diversified, Conglomerates and Traditional Conglomerates.
Company details
Balaxi was established in 1942 in Hyderabad, India, by Ashish Maheshwari as founder and managing director. Operations are centered on the pharmaceutical sector, where drug distribution and storage services are managed. These activities support supply chain needs for medications, with a focus on reliable logistics and compliance in the Indian market. The companys domain, balaxipharma.in, facilitates online access to its offerings.
- Headquarters Hyderabad, India
- Employees 197
- Founders Ashish Maheshwari
- Stage Public
- SectorsHealthcare
- Website balaxipharma.in
- Social LinkedIn Facebook Instagram
- Legal Name Balaxi Pharmaceuticals Limited
- Market Cap₹146 Cr
BALAXI · NSE
- Share Price₹31.65
+19.57% today
- Revenue₹270 Cr
FY 2025-26 · -7.7% YoY
- EBITDA₹8.52 Cr
Margin 3.1%
- Net Profit₹1.42 Cr
FY 2025-26 · -94.4% YoY
- P/E (TTM)38.5x
P/B 0.5x
- ROE0.6%
ROCE 3.5%
- Debt / Equity0.23
Interest cover 66.8x
- Employee Count197
Associated legal entities of Balaxi
Balaxi operates through Balaxi Pharmaceuticals Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Balaxi Pharmaceuticals Limited Listed CIN L25191TG1942PLC121598 | Active | 28 Sep 1942 | Hyderabad, Telangana | ₹273 Cr | 49 | 8 | View details |
Products & Services of Balaxi
Balaxi offers a comprehensive portfolio of products and services, including Pharmaceutical Products and Branded Consumer Products.
A portfolio of over 300 products across therapeutic areas is managed for distribution in frontier markets.
Products such as oral care items are distributed globally to serve consumer needs.
Board of directors of Balaxi Pharmaceuticals Limited (Balaxi)
Balaxi Pharmaceuticals Limited is the primary company behind Balaxi. The board of Balaxi Pharmaceuticals Limited currently have 6 directors; the longest-serving is Ashish Maheshwari, appointed in 2017. 21 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Ashish Maheshwari DIN 01575984 | Managing Director | 04 May 2017 | 9 yrs 6 mo | Balaxi Pharmaceuticals Limited |
| Minoshi Maheshwari DIN 01575975 | Director | 04 May 2017 | 9 yrs 6 mo | Balaxi Pharmaceuticals Limited |
| Kunal Mahendra Bhakta DIN 01710557 | Director | 04 May 2017 | 9 yrs 6 mo | Balaxi Pharmaceuticals Limited |
| Gandhi Gamji DIN 01944694 | Director | 04 May 2017 | 9 yrs 6 mo | Balaxi Pharmaceuticals Limited |
| Mangina Srinivas Rao DIN 08095079 | Director | 15 Sep 2020 | 6 yrs 2 mo | Balaxi Pharmaceuticals Limited |
| Akshita Surana DIN 10026552 | Director | 05 Sep 2024 | 2 yrs 2 mo | Balaxi Pharmaceuticals Limited |
People of Balaxi
4 people are tracked at Balaxi (2 in leadership, 2 in team); the tracked headcount is 197.
| Name | Role | Group |
|---|---|---|
| Founder & Managing Director | Leadership | |
Paridhi Maheshwari | Vice President Of Business Development | Leadership |
Ram Chawla | Country Manager | Team |
Chirag Darji | Branch Manager | Team |
Complete people profiles for Balaxi
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Balaxi
Balaxi is a publicly listed company on the NSE with ticker symbol BALAXI in India, operating in the Distribution services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date03 Dec 2015
- Listed onNSE: BALAXI
- Listed entityBalaxi Pharmaceuticals Limited
- Exchange sectorDistribution services
- ISININE618N01022
- Share price₹22.18 (-0.05% on the day) · 2026-10-14
- Market capitalisation₹123 Cr
- Price to earnings10.1
- Volume (last session)8,605
Financials of Balaxi
Exchange-reported figures of Balaxi Pharmaceuticals Limited, the listed company behind Balaxi (NSE: BALAXI).
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 270 | 293 | 241 | 336 | 279 | 231 | 45.63 |
| Revenue growth | -7.7% | +21.3% | -28.3% | +20.4% | +20.8% | +407.0% | - |
| EBITDA | 8.52 | 32.22 | 6.23 | 57.41 | 50.81 | 42.67 | 8.25 |
| EBITDA margin | +3.2% | +11.0% | +2.6% | +17.1% | +18.2% | +18.5% | +18.1% |
| Profit before tax | 5.29 | 28.68 | 1.99 | 56.92 | 54.51 | 44.32 | 8.78 |
| Net profit | 1.42 | 25.16 | (49.85) | 45.96 | 47.65 | 38.13 | 6.09 |
| Net profit margin | +0.5% | +8.6% | -20.7% | +13.7% | +17.1% | +16.5% | +13.4% |
| EPS (₹) | 0.26 | 4.54 | (0.44) | 45.14 | 47.66 | 38.14 | 6.10 |
| Balance sheet | |||||||
| Total assets | 307 | 285 | 221 | 196 | 117 | 68.64 | 27.75 |
| Net worth | 249 | 232 | 201 | 183 | 113 | 64.98 | 27.75 |
| Total debt | 57.65 | 53.43 | 19.40 | 13.30 | 3.64 | 3.66 | 0.00 |
| Cash & bank | 14.56 | 39.40 | 62.29 | 28.22 | 7.19 | 1.67 | 4.00 |
| Net working capital | 223 | 219 | 174 | 151 | 81.37 | 62.74 | 26.62 |
| Cash flow | |||||||
| Cash from operations | (4.50) | (35.00) | 4.87 | 6.08 | 34.14 | 0.00 | (14.04) |
| Cash from investing | (20.78) | (21.76) | (1.05) | (10.57) | (28.45) | (5.97) | (0.18) |
| Cash from financing | 0.44 | 33.88 | 30.25 | 25.51 | (0.16) | 3.65 | 18.10 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 81.37 | 80.68 | 70.71 | 72.54 | 56.18 | 70.74 | 76.27 | 73.29 |
| Revenue growth (YoY) | +44.8% | +14.1% | -7.3% | -1.0% | -27.4% | +7.8% | - | - |
| Other income | (0.83) | (0.99) | 2.92 | 0.10 | 1.59 | (1.78) | (1.69) | 3.94 |
| EBITDA | 5.12 | 4.66 | 0.12 | 3.09 | 1.17 | 4.15 | 12.56 | 3.99 |
| EBITDA margin | +6.3% | +5.8% | +0.2% | +4.3% | +2.1% | +5.9% | +16.5% | +5.4% |
| Depreciation | 1.42 | 0.85 | 0.65 | 0.56 | 0.48 | 0.46 | 0.46 | 0.48 |
| Interest | 0.86 | 0.73 | 0.99 | 1.02 | 0.89 | 1.01 | 0.74 | 1.38 |
| Profit before tax | 2.01 | 2.09 | 1.40 | 1.61 | 1.39 | 0.90 | 9.67 | 6.07 |
| Tax | 0.87 | 0.80 | 0.79 | 1.30 | 1.16 | 0.61 | 1.02 | 0.71 |
| Net profit | 1.14 | 1.29 | 0.61 | 0.31 | 0.23 | 0.29 | 8.65 | 5.36 |
| EPS (₹) | 0.21 | 0.24 | 0.11 | 0.06 | 0.04 | 0.05 | 1.56 | 0.97 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 80.85 | 60.99 | 70.20 | 108 | 101 | 86.87 | 45.63 |
| Revenue growth | +32.6% | -13.1% | -35.1% | +6.8% | +16.6% | +90.4% | - |
| EBITDA | 0.76 | 2.61 | 5.35 | 16.87 | 17.30 | 19.02 | 8.65 |
| EBITDA margin | +0.9% | +4.3% | +7.6% | +15.6% | +17.1% | +21.9% | +19.0% |
| Profit before tax | 7.03 | 5.28 | 5.58 | 22.44 | 19.70 | 20.59 | 9.18 |
| Net profit | 5.15 | 3.60 | 3.69 | 16.21 | 14.67 | 15.13 | 6.49 |
| Net profit margin | +6.4% | +5.9% | +5.3% | +15.0% | +14.5% | +17.4% | +14.2% |
| EPS (₹) | 0.93 | 0.65 | 0.67 | 15.93 | 14.67 | 15.13 | 6.50 |
| Balance sheet | |||||||
| Total assets | 169 | 160 | 137 | 105 | 59.84 | 46.75 | 28.11 |
| Net worth | 133 | 128 | 122 | 92.11 | 57.91 | 43.25 | 28.11 |
| Total debt | 35.29 | 32.18 | 15.70 | 12.44 | 1.93 | 3.51 | 0.00 |
| Cash & bank | 5.33 | 28.69 | 44.06 | 17.88 | 0.84 | 0.48 | 3.57 |
| Net working capital | 48.31 | 106 | 107 | 74.94 | 32.04 | 26.52 | 26.91 |
| Cash flow | |||||||
| Cash from operations | 43.87 | (7.60) | (1.83) | (7.07) | 8.89 | 13.46 | (14.37) |
| Cash from investing | (67.77) | (24.98) | 0.46 | (2.29) | (6.87) | (20.03) | (0.28) |
| Cash from financing | 0.54 | 17.21 | 27.55 | 26.39 | (1.64) | 3.49 | 18.10 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 26.29 | 15.58 | 20.24 | 24.59 | 19.31 | 16.71 | 9.65 | 11.16 |
| Revenue growth (YoY) | +36.2% | -6.8% | +109.7% | +120.3% | -8.7% | -12.2% | - | - |
| Other income | 1.08 | 0.92 | 3.37 | 1.62 | 4.21 | 0.46 | 0.32 | 2.92 |
| Total expenses | 25.96 | 16.58 | 22.17 | 23.21 | 18.54 | 16.17 | 10.30 | 11.06 |
| EBITDA | 0.33 | (1.00) | (1.93) | 1.38 | 0.77 | 0.54 | (0.65) | 0.10 |
| EBITDA margin | +1.3% | -6.4% | -9.5% | +5.6% | +4.0% | +3.2% | -6.7% | +0.9% |
| Depreciation | 0.59 | 0.59 | 0.31 | 0.15 | 0.12 | 0.11 | 0.11 | 0.11 |
| Interest | 0.57 | 0.45 | 0.71 | 0.73 | 0.62 | 0.63 | 0.69 | 0.57 |
| Profit before tax | 0.25 | (1.12) | 0.42 | 2.12 | 4.24 | 0.26 | (1.13) | 2.34 |
| Tax | 0.14 | 0.14 | 0.26 | 0.59 | 0.97 | 0.06 | 0.04 | 0.59 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 81.37 | 80.68 | 70.71 | 72.54 | 56.18 | 70.74 | 76.27 | 73.29 |
| Revenue growth (YoY) | +44.8% | +14.1% | -7.3% | -1.0% | -27.4% | +7.8% | - | - |
| Other income | (0.83) | (0.99) | 2.92 | 0.10 | 1.59 | (1.78) | (1.69) | 3.94 |
| EBITDA | 5.12 | 4.66 | 0.12 | 3.09 | 1.17 | 4.15 | 12.56 | 3.99 |
| EBITDA margin | +6.3% | +5.8% | +0.2% | +4.3% | +2.1% | +5.9% | +16.5% | +5.4% |
| Depreciation | 1.42 | 0.85 | 0.65 | 0.56 | 0.48 | 0.46 | 0.46 | 0.48 |
| Interest | 0.86 | 0.73 | 0.99 | 1.02 | 0.89 | 1.01 | 0.74 | 1.38 |
| Profit before tax | 2.01 | 2.09 | 1.40 | 1.61 | 1.39 | 0.90 | 9.67 | 6.07 |
| Tax | 0.87 | 0.80 | 0.79 | 1.30 | 1.16 | 0.61 | 1.02 | 0.71 |
| Net profit | 1.14 | 1.29 | 0.61 | 0.31 | 0.23 | 0.29 | 8.65 | 5.36 |
| EPS (₹) | 0.21 | 0.24 | 0.11 | 0.06 | 0.04 | 0.05 | 1.56 | 0.97 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 270 | 293 | 241 | 336 | 279 | 231 | 45.63 |
| Revenue growth | -7.7% | +21.3% | -28.3% | +20.4% | +20.8% | +407.0% | - |
| Other income | 2.82 | 2.36 | 0.63 | 2.64 | 4.97 | 2.23 | 0.59 |
| Total expenses | 262 | 260 | 235 | 279 | 229 | 189 | 37.38 |
| Employee cost | 0.00 | 34.74 | 28.04 | 28.95 | 12.47 | 8.47 | 2.10 |
| EBITDA | 8.52 | 32.22 | 6.23 | 57.41 | 50.81 | 42.67 | 8.25 |
| EBITDA margin | +3.2% | +11.0% | +2.6% | +17.1% | +18.2% | +18.5% | +18.1% |
| Depreciation | 2.15 | 1.89 | 2.10 | 1.75 | 0.51 | 0.30 | 0.01 |
| Interest | 3.90 | 4.01 | 2.77 | 1.38 | 0.76 | 0.28 | 0.05 |
| Profit before tax | 5.29 | 28.68 | 1.99 | 56.92 | 54.51 | 44.32 | 8.78 |
| Tax | 3.87 | 3.60 | 4.40 | 10.96 | 6.86 | 6.19 | 2.69 |
| Net profit | 1.42 | 25.16 | (49.85) | 45.96 | 47.65 | 38.13 | 6.09 |
| Net profit margin | +0.5% | +8.6% | -20.7% | +13.7% | +17.1% | +16.5% | +13.4% |
| EPS (₹) | 0.26 | 4.54 | (0.44) | 45.14 | 47.66 | 38.14 | 6.10 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 11.04 | 11.04 | 10.90 | 10.18 | 10.00 | 10.00 | 10.00 |
| Reserves & surplus | 238 | 221 | 187 | 162 | 103 | 54.98 | 17.75 |
| Shareholders' funds (net worth) | 249 | 232 | 201 | 183 | 113 | 64.98 | 27.75 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 1.30 | 0.00 | 0.00 | 0.07 | 0.13 | 0.15 | 0.00 |
| Unsecured loans | 56.35 | 53.43 | 19.40 | 13.23 | 3.51 | 3.51 | 0.00 |
| Total debt | 57.65 | 53.43 | 19.40 | 13.30 | 3.64 | 3.66 | 0.00 |
| Total liabilities | 307 | 285 | 221 | 196 | 117 | 68.64 | 27.75 |
| Assets | |||||||
| Gross block | 85.81 | 42.88 | 42.98 | 43.00 | 29.23 | 2.74 | 0.19 |
| Net block | 81.68 | 40.99 | 40.88 | 41.40 | 28.76 | 2.44 | 0.19 |
| Capital work in progress | 0.00 | 22.07 | 2.31 | 2.83 | 0.57 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.42 | 0.00 |
| Inventories | 83.48 | 78.48 | 82.17 | 105 | 98.70 | 13.62 | 0.83 |
| Sundry debtors | 136 | 111 | 55.71 | 52.28 | 27.56 | 76.76 | 29.71 |
| Cash & bank balances | 14.56 | 39.40 | 62.29 | 28.22 | 7.19 | 1.67 | 4.00 |
| Loans & advances | 17.29 | 14.09 | 10.01 | 7.99 | 7.55 | 1.72 | 0.31 |
| Total current assets | 251 | 243 | 210 | 194 | 141 | 93.77 | 34.85 |
| Total current liabilities | 28.73 | 24.15 | 36.53 | 42.39 | 59.63 | 31.03 | 8.23 |
| Net working capital | 223 | 219 | 174 | 151 | 81.37 | 62.74 | 26.62 |
| Total assets | 307 | 285 | 221 | 196 | 117 | 68.64 | 27.75 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 39.40 | 62.29 | 28.21 | 7.19 | 1.66 | 3.98 | 0.10 |
| Net cash from operating activities | (4.50) | (35.00) | 4.87 | 6.08 | 34.14 | 0.00 | (14.04) |
| Net cash from investing activities | (20.78) | (21.76) | (1.05) | (10.57) | (28.45) | (5.97) | (0.18) |
| Net cash from financing activities | 0.44 | 33.88 | 30.25 | 25.51 | (0.16) | 3.65 | 18.10 |
| Net change in cash | (24.84) | (22.89) | 34.07 | 21.02 | 5.53 | (2.32) | 3.88 |
| Closing cash | 14.56 | 39.40 | 62.29 | 28.22 | 7.19 | 1.67 | 4.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -7.7% | +21.3% | -28.3% | +20.4% | +20.8% | +407.0% | - |
| EBITDA growth | -73.6% | +417.2% | -89.2% | +13.0% | +19.1% | +417.2% | - |
| PBT growth | -81.6% | +1340.7% | -96.5% | +4.4% | +23.0% | +404.8% | +258.4% |
| Net income growth | -94.4% | +150.5% | -208.5% | -3.6% | +25.0% | +526.1% | - |
| Revenue CAGR (3Y) | -7.1% | +1.6% | +1.4% | +94.6% | +173.9% | - | - |
| EBITDA CAGR (3Y) | -45.0% | -9.0% | -47.3% | +90.9% | +219.4% | - | - |
| Profitability & leverage | |||||||
| Net income margin | +0.5% | +8.6% | -1.0% | +13.7% | +17.1% | +16.5% | +13.4% |
| Return on capital employed | +3.5% | +12.9% | +20.7% | +37.3% | +59.6% | +92.6% | +56.5% |
| Return on net worth | +0.6% | +11.6% | -25.9% | +31.1% | +53.5% | +82.3% | +39.0% |
| Debt / equity | 0.23 | 0.17 | 0.09 | 0.06 | 0.04 | 0.04 | 0.00 |
| Long-term debt / equity | 0.10 | 0.06 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Interest cover | 66.85 | 11.02 | 67.07 | 2.48 | 1.51 | 0.66 | 0.61 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 4.20 | 6.81 | 5.61 | 9.32 | 17.48 | 157.90 | 456.30 |
| Inventory turnover | 3.34 | 3.64 | 2.58 | 3.30 | 4.97 | 32.02 | 109.95 |
| Debtors turnover | 2.19 | 3.51 | 4.47 | 8.43 | 5.36 | 4.35 | 2.59 |
| EPS (₹) | 0.26 | 4.54 | (0.44) | 45.14 | 47.66 | 38.14 | 6.10 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.50 | 0.00 | 0.00 |
| Book value per share (₹) | 45.12 | 41.98 | 36.26 | 169.51 | 113.16 | 64.98 | 27.75 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 26.29 | 15.58 | 20.24 | 24.59 | 19.31 | 16.71 | 9.65 | 11.16 |
| Revenue growth (YoY) | +36.2% | -6.8% | +109.7% | +120.3% | -8.7% | -12.2% | - | - |
| Other income | 1.08 | 0.92 | 3.37 | 1.62 | 4.21 | 0.46 | 0.32 | 2.92 |
| Total expenses | 25.96 | 16.58 | 22.17 | 23.21 | 18.54 | 16.17 | 10.30 | 11.06 |
| EBITDA | 0.33 | (1.00) | (1.93) | 1.38 | 0.77 | 0.54 | (0.65) | 0.10 |
| EBITDA margin | +1.3% | -6.4% | -9.5% | +5.6% | +4.0% | +3.2% | -6.7% | +0.9% |
| Depreciation | 0.59 | 0.59 | 0.31 | 0.15 | 0.12 | 0.11 | 0.11 | 0.11 |
| Interest | 0.57 | 0.45 | 0.71 | 0.73 | 0.62 | 0.63 | 0.69 | 0.57 |
| Profit before tax | 0.25 | (1.12) | 0.42 | 2.12 | 4.24 | 0.26 | (1.13) | 2.34 |
| Tax | 0.14 | 0.14 | 0.26 | 0.59 | 0.97 | 0.06 | 0.04 | 0.59 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 80.85 | 60.99 | 70.20 | 108 | 101 | 86.87 | 45.63 |
| Revenue growth | +32.6% | -13.1% | -35.1% | +6.8% | +16.6% | +90.4% | - |
| Other income | 9.67 | 5.37 | 2.40 | 6.60 | 2.75 | 1.81 | 0.59 |
| Total expenses | 80.09 | 58.38 | 64.85 | 91.27 | 83.99 | 67.85 | 36.98 |
| Employee cost | 0.00 | 4.87 | 5.04 | 4.04 | 2.90 | 1.95 | 1.75 |
| EBITDA | 0.76 | 2.61 | 5.35 | 16.87 | 17.30 | 19.02 | 8.65 |
| EBITDA margin | +0.9% | +4.3% | +7.6% | +15.6% | +17.1% | +21.9% | +19.0% |
| Depreciation | 0.70 | 0.46 | 0.51 | 0.52 | 0.25 | 0.09 | 0.01 |
| Interest | 2.70 | 2.24 | 1.66 | 0.51 | 0.10 | 0.15 | 0.05 |
| Profit before tax | 7.03 | 5.28 | 5.58 | 22.44 | 19.70 | 20.59 | 9.18 |
| Tax | 1.88 | 1.68 | 1.93 | 6.23 | 5.03 | 5.46 | 2.69 |
| Net profit | 5.15 | 3.60 | 3.69 | 16.21 | 14.67 | 15.13 | 6.49 |
| Net profit margin | +6.4% | +5.9% | +5.3% | +15.0% | +14.5% | +17.4% | +14.2% |
| EPS (₹) | 0.93 | 0.65 | 0.67 | 15.93 | 14.67 | 15.13 | 6.50 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 11.04 | 11.04 | 10.90 | 10.18 | 10.00 | 10.00 | 10.00 |
| Reserves & surplus | 122 | 117 | 107 | 71.63 | 47.91 | 33.25 | 18.11 |
| Shareholders' funds (net worth) | 133 | 128 | 122 | 92.11 | 57.91 | 43.25 | 28.11 |
| Secured loans | 1.30 | 0.00 | 0.15 | 0.49 | 0.93 | 0.00 | 0.00 |
| Unsecured loans | 33.99 | 32.18 | 15.55 | 11.95 | 1.00 | 3.51 | 0.00 |
| Total debt | 35.29 | 32.18 | 15.70 | 12.44 | 1.93 | 3.51 | 0.00 |
| Total liabilities | 169 | 160 | 137 | 105 | 59.84 | 46.75 | 28.11 |
| Assets | |||||||
| Gross block | 42.07 | 7.13 | 7.61 | 8.41 | 2.45 | 0.78 | 0.19 |
| Net block | 41.37 | 6.67 | 7.10 | 7.89 | 2.20 | 0.69 | 0.19 |
| Capital work in progress | 0.00 | 22.07 | 2.31 | 2.83 | 0.57 | 0.00 | 0.00 |
| Investments | 79.51 | 25.07 | 19.88 | 19.54 | 19.61 | 19.54 | 0.10 |
| Inventories | 0.00 | 0.00 | 0.84 | 1.49 | 0.00 | 0.02 | 0.83 |
| Sundry debtors | 64.20 | 89.92 | 76.76 | 78.29 | 52.11 | 48.13 | 31.22 |
| Cash & bank balances | 5.33 | 28.69 | 44.06 | 17.88 | 0.84 | 0.48 | 3.57 |
| Loans & advances | 1.07 | 0.99 | 1.24 | 1.36 | 1.12 | 0.05 | 1.08 |
| Total current assets | 70.60 | 120 | 123 | 99.02 | 54.07 | 48.68 | 36.70 |
| Total current liabilities | 22.29 | 13.38 | 16.08 | 24.08 | 22.03 | 22.16 | 9.79 |
| Net working capital | 48.31 | 106 | 107 | 74.94 | 32.04 | 26.52 | 26.91 |
| Total assets | 169 | 160 | 137 | 105 | 59.84 | 46.75 | 28.11 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 28.68 | 44.06 | 17.87 | 0.84 | 0.47 | 3.55 | 0.10 |
| Net cash from operating activities | 43.87 | (7.60) | (1.83) | (7.07) | 8.89 | 13.46 | (14.37) |
| Net cash from investing activities | (67.77) | (24.98) | 0.46 | (2.29) | (6.87) | (20.03) | (0.28) |
| Net cash from financing activities | 0.54 | 17.21 | 27.55 | 26.39 | (1.64) | 3.49 | 18.10 |
| Net change in cash | (23.35) | (15.37) | 26.19 | 17.04 | 0.38 | (3.08) | 3.44 |
| Closing cash | 5.33 | 28.69 | 44.06 | 17.88 | 0.84 | 0.48 | 3.57 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +32.6% | -13.1% | -35.1% | +6.8% | +16.6% | +90.4% | - |
| EBITDA growth | -70.9% | -51.2% | -68.3% | -2.5% | -9.0% | +119.9% | - |
| PBT growth | +33.1% | -5.4% | -75.1% | +13.9% | -4.3% | +124.3% | +274.7% |
| Net income growth | +43.1% | -2.4% | -77.2% | +10.5% | -3.0% | +133.1% | - |
| Revenue CAGR (3Y) | -9.2% | -15.6% | -6.9% | +33.3% | +95.3% | - | - |
| EBITDA CAGR (3Y) | -61.1% | -46.8% | -34.5% | +24.9% | +123.0% | - | - |
| Profitability & leverage | |||||||
| Net income margin | +6.4% | +5.9% | +5.2% | +15.0% | +14.5% | +17.4% | +14.2% |
| Return on capital employed | +6.1% | +5.1% | +6.0% | +27.9% | +37.2% | +55.4% | +58.4% |
| Return on net worth | +4.0% | +2.9% | +3.4% | +21.6% | +29.0% | +42.4% | +41.1% |
| Debt / equity | 0.26 | 0.19 | 0.13 | 0.10 | 0.05 | 0.05 | 0.00 |
| Long-term debt / equity | 0.01 | 0.01 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 |
| Interest cover | 1,010.34 | 104.19 | 34.30 | 3.12 | 0.59 | 0.79 | 0.58 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 3.29 | 8.28 | 8.76 | 19.92 | 62.72 | 179.11 | 456.30 |
| Inventory turnover | 0.00 | 145.21 | 60.26 | 145.15 | 10,129.00 | 204.40 | 109.95 |
| Debtors turnover | 1.05 | 0.73 | 0.91 | 1.66 | 2.02 | 2.19 | 2.49 |
| EPS (₹) | 0.93 | 0.65 | 0.67 | 15.93 | 14.67 | 15.13 | 6.50 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.50 | 0.00 | 0.00 |
| Book value per share (₹) | 24.09 | 23.16 | 21.61 | 80.35 | 57.91 | 43.25 | 28.11 |
Web traffic of Balaxi
The website of Balaxi (balaxipharma.in) receives about 1.9K visits a month.
- Monthly visits1.9K
▼ 32.9% vs previous month
Websites whose visitors overlap most with Balaxi. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| sudarshanpharma.com | 100% | 4.4K | #2,511,746 | View details | |
| innovacaptab.com | 85% | 2.7K | #6,046,003 | View details |
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as Balaxi (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Oral solid drug delivery systems are manufactured and developed. | 1985 | Mumbai, Maharashtra, India | USD 42.49 M | USD 72.52 M | 1,115 | |
Generic, semi-solid, and liquid dosage forms are manufactured. | 1990 | Bengaluru, Karnataka, India | USD 508.93 M | 4,050 | ||
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | Mumbai, Maharashtra, India | USD 6.44 B | 19,801 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Balaxi
Complete news archive for Balaxi
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Balaxi
Balaxi was founded in 1942.
Balaxi is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Balaxi has 197 employees.
The primary company behind Balaxi, Balaxi Pharmaceuticals Limited, reported revenue of ₹273 Cr for FY 2026, down 8% year on year.
Balaxi was established in 1942 in Hyderabad, India, by Ashish Maheshwari as founder and managing director. Operations are centered on the pharmaceutical sector, where drug distribution and storage services are managed. These activities support supply chain needs for medications, with a focus on reliable logistics and compliance in the Indian market. The companys domain, balaxipharma.in, facilitates online access to its offerings.
Balaxi offers Pharmaceutical Products and Branded Consumer Products.
Yes, Balaxi is publicly traded on NSE under the ticker symbol BALAXI.
Balaxi operates through Balaxi Pharmaceuticals Limited.
The legal entities of Balaxi currently have 8 directors, including Ashish Maheshwari, Mangina Srinivas Rao, Amol Anand Mantri and others.
